It Seems Shire PLC (ADR) Will Go Up. Had Bullish Options Activity

 It Seems Shire PLC (ADR) Will Go Up. Had Bullish Options Activity

In today’s session Shire PLC (ADR) (SHPG) registered an unusually high (890) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious SHPG increase. With 890 contracts traded and 4344 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: SHPG161021C00190000 closed last at: $0.85 or 55.3% down. About 139,946 shares traded hands. Shire PLC (ADR) (NASDAQ:SHPG) has risen 25.13% since March 16, 2016 and is uptrending. It has outperformed by 19.59% the S&P500.

Analysts await Shire PLC (ADR) (NASDAQ:SHPG) to report earnings on October, 28. They expect $3.14 EPS, down 3.09% or $0.10 from last year’s $3.24 per share. SHPG’s profit will be $956.67 million for 15.12 P/E if the $3.14 EPS becomes a reality. After $3.38 actual EPS reported by Shire PLC (ADR) for the previous quarter, Wall Street now forecasts -7.10% negative EPS growth.

Shire PLC (ADR) (NASDAQ:SHPG) Ratings Coverage

Out of 18 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 15 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 83% are positive. $325 is the highest target while $210 is the lowest. The $254.89 average target is 34.22% above today’s ($189.91) stock price. Shire plc (ADR) has been the topic of 28 analyst reports since July 22, 2015 according to StockzIntelligence Inc. As per Tuesday, January 12, the company rating was maintained by RBC Capital Markets. On Wednesday, October 14 the stock rating was initiated by Northland Capital with “Outperform”. The stock has “Overweight” rating given by Barclays Capital on Monday, September 21. The stock of Shire PLC (ADR) (NASDAQ:SHPG) earned “Sector Perform” rating by RBC Capital Markets on Monday, October 26. Stifel Nicolaus initiated Shire PLC (ADR) (NASDAQ:SHPG) on Thursday, May 26 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Friday, June 3. The rating was upgraded by HSBC to “Buy” on Tuesday, November 3. The rating was upgraded by Leerink Swann to “Outperform” on Tuesday, November 17. Liberum Capital initiated the stock with “Buy” rating in Friday, May 6 report. The rating was maintained by JP Morgan with “Overweight” on Friday, May 20.

According to Zacks Investment Research, “Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)”

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The company has a market cap of $57.86 billion. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It has a 30.16 P/E ratio.

SHPG Company Profile

Shire plc, incorporated on January 28, 2008, is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Firm operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

More important recent Shire PLC (ADR) (NASDAQ:SHPG) news were published by: Businessfinancenews.com which released: “Shire PLC (ADR) Future Now Rests On Xiidra” on July 12, 2016, also Barrons.com published article titled: “Shire PLC ADR”, Businessfinancenews.com published: “Shire Goes Deeper into Hemophilia Segment” on August 01, 2016. More interesting news about Shire PLC (ADR) (NASDAQ:SHPG) was released by: Businessfinancenews.com and their article: “Shire PLC (ADR): Geared up to Inflate Drug Assortment” with publication date: June 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment